title: NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
abstract: The National Comprehensive Cancer Network (NCCN) first published the NCCN Breast Cancer Treatment Guidelines in 1996. The Guidelines address the treatment of all stages of breast cancer across the spectrum of patient care and have been updated yearly. Adjuvant therapy for breast cancer has undergone an especially rapid evolution over the past few years. Therefore, the NCCN Breast Cancer Guidelines Panel was supplemented by additional experts to form the Adjuvant Therapy Task Force to provide a forum for an extended discussion and expanded input to the adjuvant therapy recommendations for the Breast Cancer Treatment Guidelines. Issues discussed included methods of risk-stratification for recurrence; how biologic markers such as HER2 status, quantitative estrogen receptor, or genetic markers can be incorporated as prognostic or predictive factors; and how age, menopausal status, and estrogen receptor levels impact benefits from chemotherapy and endocrine therapy. Additionally, the task force discussed the strategies for use of aromatase inhibitors in postmenopausal women and the potential incorporation of trastuzumab into adjuvant therapy of women with HER2/neu positive breast cancer. This supplement summarizes the background data and ensuing discussion from the Adjuvant Task Force meeting.
authors.affiliation: Stanford Hospital and Clinics, Stanford University, Stanford, CA, USA.
authors.forename: Robert W
authors.initials: RW
authors.lastname: Carlson
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Brown
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
authors.forename: William J
authors.initials: WJ
authors.lastname: Gradishar
authors.forename: Clifford A
authors.initials: CA
authors.lastname: Hudis
authors.forename: Charles
authors.initials: C
authors.lastname: Loprinzi
authors.forename: Eleftherios Paul
authors.initials: EP
authors.lastname: Mamounas
authors.forename: Edith A
authors.initials: EA
authors.lastname: Perez
authors.forename: Kathleen
authors.initials: K
authors.lastname: Pritchard
authors.forename: Peter
authors.initials: P
authors.lastname: Ravdin
authors.forename: Abram
authors.initials: A
authors.lastname: Recht
authors.forename: George
authors.initials: G
authors.lastname: Somlo
authors.forename: Richard L
authors.initials: RL
authors.lastname: Theriault
authors.forename: Eric P
authors.initials: EP
authors.lastname: Winer
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Wolff
mesh_terms: D000328:Adult; D026683:Advisory Committees; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016019:Survival Analysis